Biogen stock traded lower as the market repriced the company after announcing an agreement to acquire Apellis Pharmaceuticals for about $5.6 billion in cash. The deal adds Apellis’ commercial complement franchise and positions Biogen more directly in immunology/rare disease and nephrology, but the immediate reaction reflected concern about near-term execution risk, capital allocation, and the time needed to realize the growth and cost synergies implied by the strategy. (globenewswire.com)

Biogen agreed to pay $41.00 per Apellis share in cash plus a contingent value right worth up to $4.00 tied to future SYFOVRE sales milestones, with closing targeted for Q2 2026. Biogen highlighted that Apellis’ products generated $689 million in 2025 revenue and are expected to grow at a mid-to-high teens rate at least through 2028, but investors are weighing whether that growth profile is enough to justify the cash outlay and integration complexity. (globenewswire.com)

Trading also reflected near-term catalyst positioning ahead of an FDA decision expected April 3, 2026 for a higher-dose regimen of nusinersen (Spinraza). Even with positive clinical read-through and recent regulatory momentum, biotech stocks often see profits taken into binary events; with the Apellis deal now absorbing investor attention, some holders appeared to reduce exposure rather than carry additional catalyst risk. (investing.com)

Near-term focus is on how Biogen plans to fund the acquisition and whether management can communicate a clear path to accretion while protecting flexibility for pipeline investment and buybacks. Investors will also be watching the FDA’s April 3 decision for higher-dose Spinraza and any updated commentary on expected franchise dynamics following the approval, as well as early signals on how Apellis’ commercial trajectory fits into Biogen’s 2026 transition-year outlook. (globenewswire.com)